JP2024516575A - 最適化されたｔｌｒ７リガンド及びその使用 - Google Patents

最適化されたｔｌｒ７リガンド及びその使用 Download PDF

Info

Publication number
JP2024516575A
JP2024516575A JP2023562827A JP2023562827A JP2024516575A JP 2024516575 A JP2024516575 A JP 2024516575A JP 2023562827 A JP2023562827 A JP 2023562827A JP 2023562827 A JP2023562827 A JP 2023562827A JP 2024516575 A JP2024516575 A JP 2024516575A
Authority
JP
Japan
Prior art keywords
tlr7
nucleotide sequence
seq
motif
immunomodulatory composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562827A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516575A5 (enExample
Inventor
エミリー クレイン フロイント，
アンナ－マリア ヘルツナー，
レベッカ レイレッキ，
アン－ジェイ トン，
サラ ウィッチナー，
レリア イヴォンヌ ドゥラマーレ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2024516575A publication Critical patent/JP2024516575A/ja
Publication of JP2024516575A5 publication Critical patent/JP2024516575A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023562827A 2021-04-16 2022-04-15 最適化されたｔｌｒ７リガンド及びその使用 Pending JP2024516575A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163176128P 2021-04-16 2021-04-16
US63/176,128 2021-04-16
PCT/US2022/025128 WO2022221736A2 (en) 2021-04-16 2022-04-15 Optimized tlr7 ligands and uses thereof

Publications (2)

Publication Number Publication Date
JP2024516575A true JP2024516575A (ja) 2024-04-16
JP2024516575A5 JP2024516575A5 (enExample) 2025-04-18

Family

ID=81940670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562827A Pending JP2024516575A (ja) 2021-04-16 2022-04-15 最適化されたｔｌｒ７リガンド及びその使用

Country Status (5)

Country Link
US (1) US20240042019A1 (enExample)
EP (1) EP4323525A2 (enExample)
JP (1) JP2024516575A (enExample)
CN (1) CN117203340A (enExample)
WO (1) WO2022221736A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4601656A1 (en) * 2022-10-12 2025-08-20 Pharmorage Pty Limited Modified oligonucleotides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007526253A (ja) * 2004-02-19 2007-09-13 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激性ウイルスｒｎａオリゴヌクレオチド
JP2008523094A (ja) * 2004-12-09 2008-07-03 アルナイラム ファーマシューティカルズ インコーポレイテッド 哺乳類における免疫応答誘導組成物および方法、ならびに短鎖干渉ｒｎａなどのオリゴヌクレオチド剤に対する免疫応答の回避方法
WO2010105819A1 (en) * 2009-03-17 2010-09-23 Gunther Hartmann Tlr7 ligand and uses thereof
JP2012517226A (ja) * 2009-02-10 2012-08-02 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ７の合成ｒｎａベースのアゴニスト

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2311848T3 (da) 2002-12-23 2013-10-14 Vical Inc Kodon-optimerede polynukleotidbaserede vacciner mod human cytomegalovirus-infektion
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
JP5331340B2 (ja) 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
EP1924284A1 (en) * 2005-09-14 2008-05-28 Hartmann, Gunther Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides
EP2357231A2 (en) * 2007-07-09 2011-08-17 Idera Pharmaceuticals, Inc. Stabilized immune modulatory RNA (SIMRA) compounds
WO2009132206A1 (en) 2008-04-25 2009-10-29 Liquidia Technologies, Inc. Compositions and methods for intracellular delivery and release of cargo
US9187746B2 (en) * 2009-09-22 2015-11-17 Alnylam Pharmaceuticals, Inc. Dual targeting siRNA agents
AU2014348212C1 (en) 2013-11-18 2018-11-29 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
CA3043033A1 (en) 2016-11-10 2018-05-17 Translate Bio, Inc. Improved ice-based lipid nanoparticle formulation for delivery of mrna
US20220177423A1 (en) 2019-04-18 2022-06-09 Translate Bio, Inc. Cystine cationic lipids
EP3959314A4 (en) 2019-04-26 2023-02-08 Genevant Sciences Gmbh LIPIDNANOPARTICLES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007526253A (ja) * 2004-02-19 2007-09-13 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激性ウイルスｒｎａオリゴヌクレオチド
JP2008523094A (ja) * 2004-12-09 2008-07-03 アルナイラム ファーマシューティカルズ インコーポレイテッド 哺乳類における免疫応答誘導組成物および方法、ならびに短鎖干渉ｒｎａなどのオリゴヌクレオチド剤に対する免疫応答の回避方法
JP2012517226A (ja) * 2009-02-10 2012-08-02 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ７の合成ｒｎａベースのアゴニスト
WO2010105819A1 (en) * 2009-03-17 2010-09-23 Gunther Hartmann Tlr7 ligand and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CELL REPORTS, vol. 25, no. 12, JPN6026011599, 2018, pages 3371 - 3381, ISSN: 0005829018 *
J. IMMUNOL., vol. 180, no. 6, JPN6026011598, 2008, pages 3729 - 3738, ISSN: 0005829017 *

Also Published As

Publication number Publication date
WO2022221736A2 (en) 2022-10-20
US20240042019A1 (en) 2024-02-08
WO2022221736A3 (en) 2023-01-05
CN117203340A (zh) 2023-12-08
EP4323525A2 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
JP7586883B2 (ja) 免疫調節ポリペプチドをコードするｍＲＮＡの組み合わせ及びその使用
CA3144902A1 (en) Rna combinations and compositions with decreased immunostimulatory properties
JP7285220B2 (ja) 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
US10973917B2 (en) MRNA combination therapy for the treatment of cancer
US20210128721A1 (en) Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
JP2023072056A (ja) インターロイキン－１２（ｉｌ１２）をコードするポリヌクレオチドおよびその使用
KR20190133699A (ko) Crispr-연관 단백질을 암호화하는 핵산 및 이의 용도
WO2018232355A1 (en) Rna antibodies
EP3468537A1 (en) Stabilized formulations of lipid nanoparticles
CN112543650A (zh) 基因组编辑的方法和组合物
JP2023527875A (ja) フェニルアラニンヒドロキシラーゼバリアント及びその使用
CA3058018A1 (en) P-ethoxy nucleic acids for stat3 inhibition
US11802146B2 (en) Polynucleotides encoding anti-chikungunya virus antibodies
JP2023512072A (ja) 代謝リプログラミングポリペプチドをコードするｍＲＮＡ及びその使用
US20240358797A1 (en) Oncoselective cancer therapy
US20240042019A1 (en) Optimized tlr7 ligands and uses thereof
JP2019533663A (ja) 核酸アジュバントを送達するための細菌ミニ細胞およびその使用方法
US8883989B2 (en) Fractalkine binding polynucleotides and methods of use
WO2025226878A2 (en) Compositions and methods for delivering dna
WO2023077170A1 (en) Polynucleotides encoding integrin beta-6 and methods of use thereof
HK40005571A (en) Combinations of mrnas encoding immune modulating polypeptides and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250410

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260331